OncLive Peer Exchange®

This program provides a comprehensive overview of the rapidly evolving landscape of colorectal cancer (CRC) care, highlighting recent advances in biomarkers, targeted therapies, and circulating tumor DNA (ctDNA) applications. Experts discuss the latest clinical trial data, including new therapeutic options in the refractory metastatic setting, offering insights into the nuances of efficacy, tolerability, and patient selection. The conversation also explores the expanding role of ctDNA in detecting minimal residual disease (MRD), guiding adjuvant therapy decisions, and informing surveillance strategies, while addressing the challenges of assay variability, interpretation, and clinical implementation. Throughout the program, the panel emphasizes the importance of individualized, data-driven decision-making, the evolving nature of clinical tools, and the potential for novel approaches to improve patient outcomes. Listeners gain both a detailed understanding of current evidence and a forward-looking perspective on innovations poised to shape CRC management.

This OncLive Peer Exchange program features expert discussion on the evolving management of metastatic pancreatic ductal adenocarcinoma. Faculty compare Nalirifox and FOLFIRINOX using clinical trial and real world evidence, address practical considerations in treatment delivery and toxicity management, and explore sequencing strategies and future therapeutic approaches. The program provides actionable insights to support individualized, evidence based care in everyday oncology practice.

This educational activity covers important updates in triple-negative breast cancer (TNBC). Expert faculty discuss recent developments in both early-stage and metastatic TNBC. Clinical trial data with antibody-drug conjugates are explored by breast oncologists. Important takeaways from the clinical trials and how they will carry over into clinical practice are assessed.

This OncLive Peer Exchange® program focuses on rapidly evolving treatment strategies for HER2-positive breast cancer across metastatic and curative settings. Dr. Joyce O’Shaughnessy and Dr. Ruta Rao review the long-standing CLEOPATRA regimen as the historical first-line standard while highlighting significant unmet needs, including CNS metastases, optimal sequencing, and long-term maintenance strategies. They discuss pivotal new data from DESTINY-Breast09, PATINA, HER2CLIMB-05, and multiple DESTINY trials that are reshaping practice by extending progression-free survival and improving outcomes in high-risk populations. The conversation explores how antibody-drug conjugates, CDK4/6 inhibitors, tyrosine kinase inhibitors, and endocrine therapy may be optimally integrated based on hormone receptor status, tumor burden, and molecular features such as PIK3CA mutations. In the curative setting, neoadjuvant and adjuvant data with trastuzumab deruxtecan demonstrate unprecedented pathologic complete response and disease-free survival rates. The program highlights a paradigm shift toward more personalized, biologically driven treatment and maintenance strategies that balance efficacy, toxicity, and quality of life.

This comprehensive panel discussion explored contemporary and emerging treatment strategies for acute myeloid leukemia (AML), focusing on the expanding role of targeted therapies, optimized venetoclax-based regimens, menin inhibitors, triplet combinations, transplant sequencing, and real-world implementation challenges. Experts examined how genomic profiling, disease biology, and patient fitness increasingly dictate individualized therapy selection. They reviewed data from early-phase studies, retrospective analyses, and large cooperative group trials, highlighting how improved tolerability and deeper remissions are reshaping frontline and relapsed AML management. Special emphasis was placed on understanding how molecular subsets, such as KMT2A rearrangements, NPM1 mutations, TP53 mutations, RAS-pathway lesions, and secondary-type mutations, respond to novel agents. Discussions also addressed outpatient monitoring, mitigating toxicity, evolving measurable residual disease (MRD)-driven strategies, and ongoing phase 3 trials that could shift standards of care. Overall, the program discusses a rapidly accelerating transition toward biology-driven, less intensive regimens.

This program offers an in-depth, expert-driven exploration of the evolving treatment landscape for chronic lymphocytic leukemia (CLL), highlighting how targeted therapies are reshaping standards of care across frontline, relapsed, and refractory settings. Through panel discussion and analysis, leading clinicians examine the roles of covalent and non-covalent BTK inhibitors, venetoclax-based regimens, and the recently FDA-approved pirtobrutinib. The panel reviews emerging evidence for sequencing therapies, monitoring resistance, and incorporating time-limited approaches, as well as how patient-specific factors such as age, frailty, comorbidities, cytogenetics, and treatment history guide decision-making. Special emphasis is placed on real-world outcomes, retreatment considerations, MRD-guided strategies, and the future integration of cellular therapies, bispecific antibodies, and BTK degraders. The session also highlights practical co-management strategies between academic and community clinicians and identifies high-priority unmet needs, including Richter’s transformation and later-line therapeutic innovation.

Panelists discuss the role of ADCs in solid tumor care, explore the ocular adverse events associated with these agents, and discuss best practices for monitoring and managing ocular toxicities in clinical practice.

Panelists discuss modern multidisciplinary strategies in neuroendocrine tumors, with a focus on evolving guidelines, immunotherapy, and patient-centered care.

• Explore the current treatment landscape of muscle-invasive bladder cancer
• Examine the emerging role of ctDNA and MRD testing in bladder cancer disease monitoring and treatment selection
• Discuss strategies for implementing novel testing approaches into clinical practice

Panelists discuss the evolving multidisciplinary management of cutaneous squamous cell carcinoma, emphasizing diagnostic precision, timely referral, and the expanding role of immunotherapy and coordinated care in improving outcomes for high-risk and advanced disease.

Panelists discuss the evolving management of advanced and metastatic non–small cell lung cancer driven by key oncogenic alterations, emphasizing advancements in molecular diagnostics, targeted treatment development, resistance mechanisms, and personalized sequencing strategies that continue to redefine the modern standard of care.

Panelists are going to discuss recent updates in the treatment of breast cancer, focusing on the key updates for HER2-targeting therapies. We will discuss the data in the context of the evolving landscape and its impact on clinical practice.

Experts discuss the multidisciplinary management of diffuse midline glioma with H3K27M mutation, addressing the unique challenges faced by community oncologists and exploring emerging therapies aimed at improving outcomes for this aggressive tumor.

Funding support provided by Chimerix/Jazz Pharmaceuticals. Content independently developed and published by OncLive.

Panelists discuss how comprehensive biomarker testing is essential for all patients with early-stage non–small cell lung cancer, with thoracic specialists emphasizing the importance of testing primary tumor samples and lymph nodes to identify actionable mutations that guide treatment decisions and inform patients about their therapeutic journey, particularly as targeted therapies and immunotherapies continue to advance in early-stage and locally advanced disease settings.

Panelists discuss how durvalumab consolidation has become standard of care for limited-stage small cell lung cancer following the ADRIATIC trial while emphasizing the importance of ensuring all eligible patients receive first-line immunotherapy in extensive-stage disease, managing emerging toxicities like pneumonitis through multidisciplinary collaboration, implementing novel therapies such as tarlatamab with appropriate infrastructure and patient selection, and optimizing sequencing strategies for the expanding arsenal of treatments including antibody-drug conjugates, T-cell engagers, and investigational agents that are transforming the previously limited therapeutic landscape of this aggressive malignancy.

Experts explore the current frontline treatment options for EGFR-targeted therapy, examine when combination therapy may be preferred, and discuss the importance of appropriately sequencing therapies for our patients.

Panelists discuss the limitations of conventional IHC in assessing TROP2 expression, the advantages of Quantitative Continuous Scoring (QCS) in improving detection accuracy, emerging clinical data supporting TROP2 NMR as a predictive biomarker for Dato-DXd, and future considerations for integrating these tools into patient selection and treatment strategies.

Callie Coombs, MD; Nicole Lamanna, MD; Sameer A. Parikh, MBBS; Joanna M. Rhodes, MD, MSCE; and Mazyar Shadman, MD, MPH, discuss how to optimize chronic lymphocytic leukemia (CLL) treatment by incorporating prognostic biomarkers like TP53 status and IGHV mutation testing into therapy selection, weighing the benefits of continuous Bruton tyrosine kinase inhibitor therapy vs fixed-duration oral doublet regimens, managing treatment toxicities and resistance patterns, and sequencing therapies in the relapsed/refractory setting based on emerging clinical trial data presented at the European Hematology Association 2025 Congress (EHA 2025).

Sagar Lonial, MD, FACP, FASCO; Adrianna Rossi, MD; Ajay K. Nooka, MD, MPH, FACP; and Cesar Rodriguez, MD, discuss how evolving treatment strategies in multiple myeloma are shifting toward quadruplet therapy regimens for newly diagnosed patients, with CAR T-cell therapy being used increasingly in earlier lines of treatment for high-risk disease. They emphasize the importance of achieving MRD negativity and personalizing treatment approaches based on patient fitness rather than strict transplant eligibility criteria.

Petros Grivas, MD, PhD; Rana R. McKay, MD; Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS discuss how to personalize treatment intensification in metastatic castration-sensitive prostate cancer by considering clinical factors like disease volume, patient fitness, genomic biomarkers, and emerging trial data to guide decisions between doublet versus triplet therapy regimens.

Tina Cascone, MD, PhD; Josh Reuss, MD; Wade Iams, MD, MSCI; Aditya Juloori, Tina Cascone, MD, PhD; Josh Reuss, MD; Wade Iams, MD, MSCI; Aditya Juloori, MD; Brendon Stiles, MD; and Mara Antonoff, MD, FACS, discuss how the evolving landscape of early-stage non–small cell lung cancer (NSCLC) treatment has been transformed by neoadjuvant and perioperative chemoimmunotherapy approaches, with recent data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from CheckMate 816 and CheckMate 77T demonstrating significant overall survival benefits while highlighting the critical importance of multidisciplinary collaboration, biomarker-guided personalization, and managing surgical attrition rates to optimize patient outcomes.

Panelists discuss the significant advancements in metastatic melanoma treatment over the past decade, including targeted therapies and immunotherapy, to help clinicians navigate the evolving therapeutic landscape and improve patient outcomes.

Sam Klempner, MD; Michael K. Gibson, MD, PhD; Kaitlyn Kelly, MD, MAS; and Nataliya Uboha, MD, PhD, discuss how the positive results from the phase 3 MATTERHORN trial, which demonstrated that adding durvalumab to perioperative FLOT chemotherapy significantly improved event-free survival in patients with resectable gastric and gastroesophageal junction cancers, establishes a new standard of care that they plan to implement in clinical practice while addressing practical considerations around patient selection, multidisciplinary coordination, and managing the toxicity profile of this combination regimen.

Panelists discuss the evolving landscape of breast cancer surveillance, focusing on circulating tumor DNA testing for molecular residual disease detection, recent clinical data supporting its use, and practical strategies for integrating this technology into posttreatment monitoring.

Panelists discussed evolving strategies in limited-stage and extensive-stage small cell lung cancer (LS-SCLC and ES-SCLC), including the integration of consolidation durvalumab in LS-SCLC, emerging first-line chemoimmunotherapy regimens in ES-SCLC, maintenance strategies such as atezolizumab plus lurbinectedin and durvalumab plus tarlatamab (DeLLphi-305), and the promising future role of novel agents like T-cell engagers, antibody-drug conjugates, and B7-H3–targeted therapies (including DeLLphi-304) in reshaping the treatment landscape.

Shreyaskumar R. Patel, MD; Priscilla Merriam, MD; Richard F. Riedel, MD; and Gina Z. D'Amato, MD, discuss how gastrointestinal stromal tumors require comprehensive mutational analysis to guide targeted kinase inhibitor therapy, emphasizing the importance of patient adherence, proactive adverse effect management, and maintaining some form of kinase inhibition even after progression to maximize disease control and quality of life.

Joshua Sabari, MD; Christine Bestvina, MD; Hatim Husain, MD; and Julia Rotow, MD, discuss how targeted therapies for KRAS G12C and ALK::ROS1 fusion-positive advanced non–small cell lung cancer are evolving from second-line treatments to promising frontline combinations with immunotherapy, emphasizing the critical importance of comprehensive biomarker testing and the management of unique toxicity profiles as these next-generation inhibitors demonstrate improved efficacy and central nervous system penetration.

Panelists discuss the latest data on first-line treatment options for EGFR-mutated NSCLC, including CNS efficacy, and explore strategies for managing adverse events and sequencing therapies to optimize long-term outcomes.

Heather McArthur, MD; Laura Huppert, MD; Ruta Rao, MD; William J. Gradishar, MD, FACP; and VK Gadi, MD, PhD, discuss how recent ASCO 2025 data from DESTINY-Breast09 and other studies are reshaping first-line treatment decisions for HER2-positive metastatic breast cancer, with experts debating optimal sequencing strategies between trastuzumab deruxtecan (T-DXd), the CLEOPATRA regimen, and CDK4/6 inhibitor combinations while considering patient-specific factors like central nervous system metastases, hormone receptor status, and quality of life preferences.